ブロンテ・キャピタルはレジェネロン株を146.57万ドルに増やし,12.2%の保有額となり, 株当たり利益が予想を上回り, 機関の所有権は83.31%に上昇しました. Bronte Capital increased its Regeneron stake to $146.57m, 12.2% holdings, as earning per share surpassed expectations and institutions' ownership rose to 83.31%.

ブロンテ・キャピタル・マネジメントは レジェネロン・ファーマシューティカルズの 株式を146.570万ドルに増やし 保有額の12.2%を占める Bronte Capital Management has increased its stake in Regeneron Pharmaceuticals to $146.57 million, representing 12.2% of its holdings. 同社は,株当たり11.56ドルの利益を報告し,予想の8.93ドルを上回った. The company reported earnings of $11.56 per share, surpassing expectations of $8.93. いくつかの機関投資家がポジションを調整し,レジェネロンは現在83.31%を機関が所有しています. Several institutional investors have adjusted their positions, with Regeneron now 83.31% owned by institutions. 分析者は株価目標値を上げ, 総合意で1,109.70ドルにしました. 収益の強い成長と市場情勢の好調を反映しています. Analysts have raised price targets for the stock, with a consensus of $1,109.70, reflecting strong revenue growth and positive market sentiment.